Risks
4 risks
Risk Intelligence
Formulary exclusions for insulin aspart
View Risks →Biocon Limited — Q2 FY26
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generics (+24% YoY).
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generics (+24% YoY). Biosimilar EBITDA margin expanded ~400bps to 25% on operating leverage. The balance sheet strengthened via structured debt repayment (Goldman Sachs, Kotak, Edelweiss), with annual interest savings of ~₹300 crore expected from FY27. Key launches included Ustekinumab, Aspart, Bevacizumab, and Aflibercept; Denosumab approval and CalRx insulin glargine partnership mark strategic wins. Syngene's CRDMO grew modestly at 2% but maintained FY26 guidance. Risks include competitive pricing pressure in biosimilars and potential formulary exclusions for insulin aspart.
बायोकॉन ने वित्त वर्ष 2026 की दूसरी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कुल कमाई ₹4,296 करोड़ रही, जो पिछले साल से 20% ज्यादा है। कमाई पर खर्च घटाने के बाद बचा मुनाफा (EBITDA) ₹928 करोड़ रहा, जो 29% बढ़ा। यह बढ़ोतरी बायोसिमिलर (25% बढ़ोतरी) और जेनेरिक दवाओं (24% बढ़ोतरी) की वजह से हुई। बायोसिमिलर में मुनाफा बढ़ाने की क्षमता (EBITDA मार्जिन) 25% हो गई, जो पहले से 4% ज्यादा है। कंपनी ने गोल्डमैन सैक्स, कोटक और एडलवाइस जैसे कर्ज चुकाए, जिससे अगले साल से हर साल लगभग ₹300 करोड़ ब्याज बचेगा। नई दवाओं (जैसे उस्टेकिनुमैब, एस्पार्ट) की लॉन्चिंग और डेनोसुमैब की मंजूरी से फायदा हुआ। सिंजीन का कारोबार धीमा (2% बढ़ोतरी) रहा, लेकिन उसने अपना सालाना लक्ष्य बरकरार रखा। जोखिम: बायोसिमिलर में कड़ी प्रतिस्पर्धा और इंसुलिन एस्पार्ट के बाजार से बाहर होने का खतरा।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Biosimilar Revenue Growth
₹2,721 crore
+25% YoY
Biosimilars segment revenue grew 25% year-on-year, led by strong performance in North America and Europe.
Biosimilar EBITDA Margin
25%
+400bps YoY
EBITDA margin expanded ~400 basis points year-on-year due to improved operating leverage.
Yesintek Formulary Coverage
>70%
N/A
Yesintek (Ustekinumab) secured over 70% commercial formulary coverage in the U.S., indicating strong market adoption.
Interest Cost Savings (FY27)
₹300 crore
N/A
Annual interest cost savings of ~₹300 crore expected from FY27 after structured debt repayment.
What Changed vs Last Quarter
NEW
Biosimilar R&D spend at 7-9% of revenue
Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
NEW
Generics R&D spend at 8-10% of revenue
Generics R&D spend is expected to be in the 8-10% range of segment revenue.
NEW
Generics gross margin improvement in H2
Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.
NEW
Syngene maintains FY26 annual guidance
Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.
DROPPED
Generics double-digit revenue growth for FY26
Management expects strong double-digit revenue growth for the generics segment for the full fiscal year, driven by multiple product launches including liraglutide in Europe and the U.S.
DROPPED
Liraglutide U.S. approval expected this fiscal
Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.
DROPPED
Denosumab U.S. approval by end of calendar 2025
Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.
DROPPED
Semaglutide filings in Q2 FY26 for emerging markets and Canada
Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.
NEW RISK
Formulary exclusions for insulin aspart
Top formularies like Optum Rx and Express Scripts have excluded aspart as a class, potentially limiting TAM for Kirsty.
NEW RISK
Competitive pricing pressure in biosimilars
Market share and ASPs are inversely proportional; increased competition could erode pricing and margins.
NEW RISK
Denosumab market crowded with five players
Five players are already in the Denosumab market with five more in the pipeline, increasing competitive intensity.
RISK GONE
Adalimumab (Hulio) U.S. market share challenges
Adalimumab in the U.S. remains a work in progress with pricing pressure and dominance of private labelers (Sandoz/CVS); market share gains uncertain.
RISK GONE
Regulatory delays for GLP-1 approvals in Canada
Health Canada has not approved any generic GLP-1; semaglutide approval may be delayed beyond best-case timeline of end-2026.
RISK GONE
High debt burden at Biocon Biologics
Net debt of $1.15 billion at Biocon Biologics continues to weigh on consolidated financials, though QIP and structured equity repayments are expected to reduce interest costs gradually.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25
Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.
Mentioned in Q1 FY26, Q4 FY25
Adalimumab in the U.S. remains a work in progress with pricing pressure and dominance of private labelers (Sandoz/CVS); market share gains uncertain.
Mentioned in Q1 FY25, Q2 FY25
Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics recovery from new launches.
Mentioned in Q2 FY25, Q3 FY25
Generics business expected to return to mid-teens growth in FY26, driven by liraglutide and other launches.
Mentioned in Q2 FY25, Q3 FY25
Consolidated net debt stands at ~$1.3 billion, with additional short-term borrowing for stake purchase, increasing financial leverage.
Fast read
Guidance and risk preview
Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
Top formularies like Optum Rx and Express Scripts have excluded aspart as a class, potentially limiting TAM for Kirsty.
View Risks →